Health Care Deal News, October 21, 2013 - Antibody-Drug Conjugates were all the Acquisition Rage Last Week, Fortis Healthcare is Selling Quality HealthCare Medical Services, MedImmune, Inc. was Busy This Week

 

Brought to you by www.DealSearchOnline.com
 

October 21, 2013 Issue:

 

Recent Health Care M&A Deals

Biotechnology

 

 

Acquirer

Target

Price

Mesoblast Limited

Stem Cell Therapeutic Business

$50 million

MedImmune, Inc.

ADC Therapeutics

$20 million

MedImmune, Inc.

Spirogen

$200 million

 

 

 

Hospitals

 

 

Acquirer

Target

Price

Bupa

Quality Healthcare

$355 million

 

 

 

Medical Devices

 

 

Acquirer

Target

Price

Brookhaven Medical, Inc.

Wound Management Technologies

Merger

 

Technology Deal of the Week
Antibody-drug conjugates (ADCs)—a cancer drug technology that targets cancer cells—were all the acquisition rage last week. First, Novartis (NYSE: NVS) announced it secured the rights to ADC technology from ImmunoGen, Inc. (NASDAQ: IMGN) for an undisclosed amount. Then, MedImmune, Inc. (NYSE: AZN) announced it would acquire a portfolio company of Auven Therapeutics, a private equity firm based in St. Thomas, U.S. Virgin Islands. That deal, at $200 million, was for Spirogen, which develops ADCs. At the same time, MedImmune announced its $20 million collaboration with another Auven company, ADC Therapeutics, for work on two ADC programs that are now in preclinical development....Want to read more news? Click here for a free trial to The Health Care M&A Information Source and download the current issue today.

 

Charted Territory
“Bolt-ons” were the byword back in January, as the big biotech and pharma companies swore off mega-mergers and instead said they were looking for more strategic deals. So why was it “news” last week when Roche (SIX: RO) CEO Severin Schwan told an analyst call that his company preferred bolt-on acquisitions to mega-mergers? Perhaps because his company is following that philosophy. Here’s a look at the 10 biggest deals announced so far this year in the Biotechnology and Pharmaceutical sectors. See if you can find the mega-mergers.

 

10 Largest Biotech and Pharma Transactions in 2013, through October 18

Acquirer

Target

Price

Thermo Fisher Scientific

Life Technologies Corp.

$15.8 billion

Amgen, Inc.

Onyx Pharmaceuticals, Inc.

$9.7 billion

Valeant Pharmaceuticals

Bausch + Lomb Holdings

$8.7 billion

Perrigo Company

Elan Corporation, plc

$8.6 billion

Actavis, Inc.

Warner Chilcott plc

$8.5 billion

Biogen Idec, Inc.

Rights to Tysabri

$3.3 billion

Mylan, Inc.

Agila Specialties Private Ltd.

$1.6 billion

CFR Pharmaceuticals SA

Adcock Ingram Holdings Ltd.

$1.3 billion

Bayer HealthCare LLC

Conceptus, Inc.

$1.1 billion

Aspen Group

Merck’s API business

$1.0 billion

Source: Health Care M&A News, October 2013

Want to read more news? Click here for a free trial to The Health Care M&A Information Source and download the current issue today

 

Services Deal of the Week
Fortis Healthcare is selling Quality HealthCare Medical Services, the largest private clinic network in Hong Kong. The lucky buyer is Bupa, the London-based international healthcare group, which agreed to pay $355 million for Quality’s 50 medical centers, more than 500 affiliated clinics, and more than 20 dental and physiotherapy centers. JP Morgan and Religare Capital Markets acted as advisors to Fortis in this transaction, which is expected to close by the end of October...Want to read more news? Click here for a free trial to The Health Care M&A Information Source and download the current issue today.

 

In the Pipeline
MedImmune, Inc., the biotech arm of AstraZeneca plc (NYSE: AZN), was busy this week. Besides its deals for two companies in Auven Therapeutics’ portfolio, its venture capital unit, MedImmune Ventures, led a Series A financing of $12.5 million for G1 Therapeutics, Inc. G1’s lead clinical candidate is a proprietary, potent and selective cyclin-dependent kinase (CDK) 4/6 inhibitor for the potential treatment of chemotherapy-induced myelosuppression. Co-investors include Hatteras Venture Partners and Mountain Group Capital...Want to read more news? Click here for a free trial to The Health Care M&A Information Source and download the current issue today.

 

7th Annual HCap Healthcare Services & Capital Conference, December 4-6, 2013, JW Marriott, Washington, D.C. (Special Offer for HCDN readers – save additional $200 off Early-Bird rate!)
Strategy, Policy, Capital and M&A for the Healthcare Continuum - Healthcare’s best and brightest from LTC & Senior Living; Home Care and Hospice; Hospitals and Health Systems; and Physician and Medical Groups will gather in Washington, D.C. to share experiences, look ahead to 2014’s changes, and to meet with Capital. 
 

Register today to:
Participate in interactive discussions with healthcare’s cutting-edge innovators, top policy makers and Wall Street analysts.
 

Meet leading lenders, iBanks, PE firms, M&A firms and other financial advisors to discuss capital for growth or acquisition purposes.
 

Discuss potential acquisitions and divestitures with other providers.
 

Engage C-Level thought leaders to share perspectives and business models and explore potential partnerships.
 

For more information and to register:  www.hcapconference.com (Use the code HCAPDN to save $200).

 

Free Trial to The Health Care M&A Information Source - Get instant access to the latest issue of The Health Care M&A News
Your free trial includes 2 monthly newsletter issues, weekly email alerts to the latest deals and developments in every key segment of the health care service and technology sectors, including behavioral health care, biotechnology, e-health, home health care, hospitals, laboratories, long-term care, managed care, medical devices, pharmaceuticals, physician medical groups, rehabilitation and more.Plus, you'll receive a sample of the Health Care M&A Quartlery Report. Visit http://www.levinassociates.com/freetrialm to sign up now.

 

Around the Web in Health Care M&A...Click here to see more

 
Webcast Calendar...Click here to see more

 

Upcoming Conference Partnerships... Click here to see more